Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1825-1831

  Brueckl, Wolfgang Michael ^a,b,c   Al Batran, Salah Eddin ^d   Ficker, Joachim Hans ^a,b,c   Claas, Silke ^e   Atmaca, Akin ^d   Hartmann, Arndt ^b,f   Rieker, Ralf Joachim ^b,f   Wirtz, Ralph Markus ^b,e,f,g  

^a 3 Nuremberg Lung Cancer Center   (Germany)

^b Friedrich Alexander University Erlangen Nuremberg   (Germany)

^c Paracelsus Medical University   (Germany)

^d KRANKENHAUS NORDWEST   (Germany)

^e STRATIFYER Molecular Pathology GmbH   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g St Elisabeth Hospital   (Germany)

Author keywords

adjuvant treatment; estrogen receptor 1 (ESR1); gene expression; non small cell lung cancer (NSCLC); prognosis

Indexed keywords

CISPLATIN; ESTROGEN RECEPTOR ALPHA; NAVELBINE;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; SYSTEMATIC REVIEW;

ADJUVANT TREATMENT; ESTROGEN RECEPTOR 1 (ESR1); GENE EXPRESSION; NON-SMALL CELL LUNG CANCER (NSCLC); PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84881554336     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28209     Document Type: Article

References (41)

1. Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-52.
2. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9.
3. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
4. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
5. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97.
6. Besse B, Le Chevalier T,. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? J Clin Oncol 2008; 26: 5014-17.
7. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28: 29-34.
8. Strauss GM, Herndon JE, II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-51.
9. Darb-Esfahani S, Wirtz RM, Sinn BV, et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer 2009; 16: 1229-39.
10. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
11. Siegfried JM, Hershberger PA, Stabile LP,. Estrogen receptor signaling in lung cancer. Semin Oncol 2009; 36: 524-31.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
13. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374: 1243-51.
14. Lee ES, Son DS, Kim SH, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008; 14: 7397-404.
15. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010; 28: 4417-24.
16. Bogush TA, Dudko EA, Beme AA, et al. Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc) 2010; 75: 1421-7.
17. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002; 73: 403-5; discussion 6.
18. Di Nunno L, Larsson LG, Rinehart JJ, et al. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000; 124: 1467-70.
19. Fasco MJ, Hurteau GJ, Spivack SD,. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002; 188: 125-40.
20. Ishibashi H, Suzuki T, Suzuki S, et al. Progesterone receptor in non-small cell lung cancer-A potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005; 65: 6450-8.
21. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005; 11: 5084-9.
22. Kawai H, Ishii A, Washiya K, et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005; 25: 4693-8.
23. Lau SK, Chu PG, Weiss LM,. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol 2006; 14: 83-7.
24. Marquez-Garban DC, Chen HW, Fishbein MC, et al. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007; 72: 135-43.
25. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001; 285: 340-7.
26. Radzikowska E, Langfort R, Giedronowicz D,. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2002; 8: 69-73.
27. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11: 7280-7.
28. Skov BG, Fischer BM, Pappot H,. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008; 59: 88-94.
29. Wu CT, Chang YL, Shih JY, et al. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005; 130: 979-86.
30. Gomez-Fernandez C, Mejias A, Walker G, et al. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl Immunohistochem Mol Morphol 2010; 18: 137-41.
31. Ollayos CW, Riordan GP, Rushin JM,. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med 1994; 118: 630-2.
32. Sica G, Wagner PL, Altorki N, et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med 2008; 132: 1889-95.
33. Stabile LP, Lyker JS, Gubish CT, et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005; 65: 1459-70.
34. Villa E, Colantoni A, Grottola A, et al. Variant estrogen receptors and their role in liver disease. Mol Cell Endocrinol 2002; 193: 65-9.
35. Sui M, Jiang D, Hinsch C, et al. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res Treat 2010; 121: 335-45.
36. Chen Y, Perng RP, Yang KY, et al. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer 2000; 29: 139-46.
37. Chen YM, Perng RP, Yang KY, et al. A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. Am J Clin Oncol 2000; 23: 13-17.
38. Traynor AM, Schiller JH, Stabile LP, et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009; 64: 51-9.
39. McClay EF, Bogart J, Herndon JE, II, et al.; Cancer and Leukemia Group B Study (9235). A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol 2005; 28: 81-90.
40. Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from amoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol 2011; 29: 4160-7.
41. Zamagni C, Wirtz RM, De Iaco P, et al. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-Adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocr Relat Cancer 2009; 16: 1241-9.